The FDA approved a new drug to treat Alzheimer’s disease in its early stages
January 6, 2023 2:39 PM ESTLecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval.
While the 27% improvement in cognitive test scores among the patients taking lecanemab compared to those receiving placebo over 18 months may not seem dramatic, it could slow decline enough to give patients months or even years of additional time with fewer memory problems.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
US approves Alzheimer’s drug that slows rate of cognitive decline\n\t\t\tKeep abreast of significant corporate, financial and political developments around the world.\n\t\t\tStay informed and spot emerging risks and opportunities with independent global reporting, expert\n\t\t\tcommentary and analysis you can trust.\n\t\t
続きを読む »
US approves honeybee vaccine against hive-destroying diseaseMaybe humans could learn a thing or two about how modern medicine can prevent the spread of disease
続きを読む »
Acupuncture could be a safe and feasible management option for IBS-DResearchers preliminarily evaluated the practicality of utilizing the United States (US) Food and Drug Administration (FDA)-advocated endpoints to assess the effectiveness of acupuncture in IBS-D (irritable bowel syndrome with diarrhea) management.
続きを読む »